Literature DB >> 15271404

Accelerated and blastic phases of chronic myelogenous leukemia.

Francis J Giles1, Jorge E Cortes, Hagop M Kantarjian, Susan M O'Brien.   

Abstract

Chronic myelogenous leukemia (CML) may have a biphasic or triphasic course, whereby patients who were initially diagnosed in the chronic phase (CP) develop more aggressive disease, frequently pass through an intermediate or accelerated phase (AP), and finally evolve into an acute leukemia like blastic phase (BP). A slowing in the rate of development of AP or BP has accompanied successive improvements in therapy for patients who have CP CML. Variable diagnostic criteria for AP and BP are used in the literature, rendering comparisons difficult. The management of patients in AP or BP consistently has been less effective than the management of those inCP for all modalities of therapy. This article reviews the current diagnostic criteria, therapeutic strategies, outcomes, and investigational therapies for AP and BP CML.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15271404     DOI: 10.1016/j.hoc.2004.03.005

Source DB:  PubMed          Journal:  Hematol Oncol Clin North Am        ISSN: 0889-8588            Impact factor:   3.722


  11 in total

1.  Sustained durability of responses and improved progression-free and overall survival with imatinib treatment for accelerated phase and blast crisis chronic myeloid leukemia: long-term follow-up of the STI571 0102 and 0109 trials.

Authors:  Richard T Silver; Jorge Cortes; Roger Waltzman; Manisha Mone; Hagop Kantarjian
Journal:  Haematologica       Date:  2009-05       Impact factor: 9.941

2.  Dasatinib in imatinib-resistant or imatinib-intolerant chronic myeloid leukemia in blast phase after 2 years of follow-up in a phase 3 study: efficacy and tolerability of 140 milligrams once daily and 70 milligrams twice daily.

Authors:  Giuseppe Saglio; Andreas Hochhaus; Yeow Tee Goh; Tamas Masszi; Ricardo Pasquini; Frederic Maloisel; Philipp Erben; Jorge Cortes; Ronald Paquette; M Brigid Bradley-Garelik; Chao Zhu; Herve Dombret
Journal:  Cancer       Date:  2010-08-15       Impact factor: 6.860

Review 3.  Blastic phase of chronic myelogenous leukemia.

Authors:  Merat Karbasian Esfahani; Evelyn L Morris; Janice P Dutcher; Peter H Wiernik
Journal:  Curr Treat Options Oncol       Date:  2006-05

4.  Identification of basophils as a major source of hepatocyte growth factor in chronic myeloid leukemia: a novel mechanism of BCR-ABL1-independent disease progression.

Authors:  Sabine Cerny-Reiterer; Viviane Ghanim; Gregor Hoermann; Karl J Aichberger; Harald Herrmann; Leonhard Muellauer; Andreas Repa; Christian Sillaber; Andrew F Walls; Matthias Mayerhofer; Peter Valent
Journal:  Neoplasia       Date:  2012-07       Impact factor: 5.715

5.  Dynamic model for predicting death within 12 months in patients with primary or post-polycythemia vera/essential thrombocythemia myelofibrosis.

Authors:  Constantine S Tam; Hagop Kantarjian; Jorge Cortes; Alice Lynn; Sherry Pierce; Lingsha Zhou; Michael J Keating; Deborah A Thomas; Srdan Verstovsek
Journal:  J Clin Oncol       Date:  2009-09-28       Impact factor: 44.544

Review 6.  Clinical profile of dasatinib in Asian and non-Asian patients with chronic myeloid leukemia.

Authors:  Dong-Wook Kim; Yeow-Tee Goh; Hui-Hua Hsiao; Priscilla B Caguioa; Dongho Kim; Wan-Seok Kim; Tapan Saikia; Shruti Agrawal; Amit Roy; David Dai; M Brigid Bradley-Garelik; Jaydip Mukhopadhyay; Saengsuree Jootar
Journal:  Int J Hematol       Date:  2009-05-20       Impact factor: 2.490

7.  Diagnostic algorithms, monitoring, prognostication, and therapy in chronic myeloid leukemia (CML): a proposal of the Austrian CML platform.

Authors:  Peter Valent; Thomas Lion; Dominik Wolf; Christian Sillaber; Hermine Agis; Andreas Petzer; Alois Lang; Peter Kalhs; Dietmar Geissler; Richard Greil; Werner Linkesch; Sonja Burgstaller; Josef Thaler; Günther Gastl
Journal:  Wien Klin Wochenschr       Date:  2008       Impact factor: 1.704

8.  Imatinib-resistant chronic myeloid leukemia (CML): Current concepts on pathogenesis and new emerging pharmacologic approaches.

Authors:  Peter Valent
Journal:  Biologics       Date:  2007-12

9.  Fangchinoline induces G0/G1 arrest by modulating the expression of CDKN1A and CCND2 in K562 human chronic myelogenous leukemia cells.

Authors:  Yuping Wang; Jie Chen; Lin Wang; Yuji Huang; Ye Leng; Guiying Wang
Journal:  Exp Ther Med       Date:  2013-01-24       Impact factor: 2.447

10.  Erythroid blast crisis in chronic myelogenous leukemia: Case report and review of literature.

Authors:  Rochelle Nagales Nagamos; Teresa Gentile; Neerja Vajpayee
Journal:  Leuk Res Rep       Date:  2016-04-27
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.